Olaris key facts
as of Oct 2026- Developer of a precision diagnostics platform designed to identify biomarkers of treatment response.
- Olaris is valued at approximately $70.0M as of Oct 2026 (last reported valuation).
- It has raised $29.0M; the latest was Later Stage VC ($15.0M) in Apr 2025.
- Notable investors include Alumni Ventures, Harvard Innovation Launch Lab, Labcorp Venture Fund, Northpoint Capital Group, U.S. Boston Growth Capital — 10 tracked in total.
- Status: Privately Held (backing).
Olaris's last reported valuation, Apr 2025. Nothing priced has surfaced since.
- ·Watch Olaris: the Monday email on marks, rounds and moves
Olaris funding rounds
No funding rounds for Olaris are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Olaris valuation
Olaris's last reported valuation was $70 million in Apr 2025. No priced round, secondary trade or fund mark has surfaced since.
Olaris investors
10 investors are on record for Olaris, including Alumni Ventures, Harvard Innovation Launch Lab, Labcorp Venture Fund and Northpoint Capital Group.
About Olaris
Developer of a precision diagnostics platform designed to identify biomarkers of treatment response. The company uses metabolite profiling and customized machine learning algorithms to determine therapy response and associated outcomes, enabling biopharmaceutical companies to improve treatment efficacy and reduce adverse events.
- Sector
- Healthcare
- HQ
- Framingham, MA, United States
- Founded
- 2014
- Employees
- 17
- Website
- myolaris.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.